跳至主要内容
临床试验/ISRCTN81883379
ISRCTN81883379已完成未知

A randomised controlled trial of adjunctive systemic therapy for vulval Erosive Lichen Planus

niversity of Nottingham (UK)0 个研究点目标入组 96 人开始时间: 2014年6月12日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
96

研究概览

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • Current inclusion criteria as of 08/12/2014:
  • 1. Clinical diagnosis of erosive lichen planus affecting the vulvovaginal region (ELPV)
  • 2. Documented histological examination in the patient’s history that excludes malignant/pre-malignant disease. Biopsy should be repeated if clinically indicated prior to consideration of systemic therapy
  • 3. Inadequate disease control despite first-line therapy with clobetasol propionate 0.05% for at least 3 months
  • 4. Moderate or severe disease on Investigator Global Assessment
  • 5. Microbiological swabs negative, or result that is not clinically relevant, at study entry
  • 6. Willing and capable of giving informed consent
  • 7. Willing to have clinical images taken
  • 8. Female aged 18 years or over
  • 9. Use of effective contraceptive methods in females of childbearing age for the duration of treatment
  • 10. For participants receiving methotrexate to use effective contraceptive methods until 6 months after the end of treatment
  • Previous inclusion criteria:
  • 1. Clinical diagnosis of erosive lichen planus affecting the vulva
  • 2. Histological examination within the past 12 months to exclude alternative diagnoses
  • 3. Inadequate control despite first-line therapy with clobetasol propionate 0.05%
  • 4. Disease severity of moderate-severe on Investigator Global Assessment
  • 5. Negative microbiological swabs at study entry
  • 6. Willing and capable of giving informed consent
  • 7. Willing to have clinical images taken
  • 8. Age >18 years (there is no upper age limit)
  • 9. Use of effective contraceptive methods in females of childbearing age
  • Target Gender: Female; Upper Age Limit 99 years ; Lower Age Limit 18 years

排除标准

  • Current exclusion criteria as of 08/12/2014:
  • 1. Cases of lichen sclerosus/lichen planus overlap
  • 2. Received one or more of the trial drugs within the last one month (excluding clobetasol propionate 0.05%)
  • 3. Previous/current diagnosis of malignant disease (skin or internal)
  • 4. History of or current diagnosis of pre-malignant vulval skin or cervical disease
  • 5. Receiving concurrent medications that would preclude the use of any of the trial medications in normal practice
  • 6. History of clinically significant renal or liver impairment or other pre-existing medical conditions that would preclude the use of any of the trial medications in normal practice
  • 7. Administration of a live vaccine (BCG, Measles, Mumps, Rubella, Yellow Fever, Oral Polio, Oral Typhoid) within the last 2 weeks
  • 8. Pregnancy or breast-feeding
  • 9. Known allergy to any of the trial medications
  • Previous exclusion criteria:
  • 1. Cases of lichen sclerosus/lichen planus overlap
  • 2. Patients taking beta blockers or non-steroidal anti-inflammatory medications
  • 3. Received one or more of the trial drugs within the last month (excluding clobetasol propionate 0.05%)
  • 4. Previous/current diagnosis of malignant disease (skin or internal)
  • 5. Pre-malignant vulval skin or cervical disease
  • 6. Receiving concurrent medications that would preclude the use of any of the trial medications in normal practice
  • 7. History of clinically significant renal or liver impairment or other pre-existing medical conditions that would preclude the use of any of the trial medications in normal practice
  • 8. Administration of a live vaccine (BCG, measles, mumps, rubella, yellow fever, oral polio, oral typhoid) within the last 2 weeks
  • 9. Pregnancy or breastfeeding
  • 10. Known sensitivity to any of the trial medications

研究者

发起方
niversity of Nottingham (UK)

相似试验